Discounted Cash Flow
Supernus Pharmaceuticals, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $210.1m | $91.2m | $65.2m | 43.4% | $1.84 |
| 2017 | $294.1m (40.0%) | $57.3m (-37.2%) | $112.6m (72.7%) | 19.5% (-55.1%) | $1.13 (-38.6%) |
| 2018 | $408.9m (39.0%) | $111.0m (93.8%) | $128.1m (13.8%) | 27.1% (39.4%) | $2.13 (88.5%) |
| 2019 | $392.8m (-3.9%) | $113.1m (1.9%) | $140.4m (9.6%) | 28.8% (6.0%) | $2.16 (1.4%) |
| 2020 | $520.4m (32.5%) | $127.0m (12.3%) | $134.9m (-3.9%) | 24.4% (-15.3%) | $2.41 (11.6%) |
| 2021 | $579.8m (11.4%) | $53.4m (-57.9%) | $127.1m (-5.8%) | 9.2% (-62.2%) | $1.01 (-58.1%) |
| 2022 | $667.2m (15.1%) | $60.7m (13.6%) | $116.4m (-8.4%) | 9.1% (-1.3%) | $1.13 (11.9%) |
| 2023 | $607.5m (-8.9%) | $1.3m (-97.8%) | $110.5m (-5.1%) | 0.2% (-97.6%) | $0.02 (-98.2%) |
| 2024 | $661.8m (8.9%) | $73.9m (5512.8%) | $171.2m (54.9%) | 11.2% (5052.4%) | $1.34 (6600.0%) |
| 2025 | $719.0m (8.6%) | $-38.5m (-152.2%) | $46.0m (-73.1%) | -5.4% (-148.0%) | $-0.68 (-150.7%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.